

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the announcement of GenFleet Therapeutics (Shanghai) Inc. (the “**Company**”) dated October 16, 2025 (the “**Announcement**”) in relation to the full exercise of the Over-allotment Option in respect of an aggregate of 13,386,000 H Shares, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment option (taking into account the full exercise of the Offer Size Adjustment Option). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Announcement.

Upon completion of full exercise of the Over-allotment Option, the registered share capital and total number of the shares of the Company were changed to RMB37,036,663 and 370,366,630 shares, respectively. To reflect such changes in the registered share capital and share capital structure of the Company, corresponding amendments were made to the articles of association of the Company (the “**Articles of Association**”).

Pursuant to the authorization granted at the general meeting held on December 3, 2024, and further authorization granted by the board of directors of the Company (the “**Board**”), the persons authorized by the Board have approved to make corresponding adjustments and amendments to the Articles of Association based on the completion of the Global Offering, including but not limited to the contents in respect of the registered share capital and shareholding structure of the Company.

Particulars of the amendments to the Articles of Association are as follows:

Article 6, which originally read as:

“The registered capital of the Company is RMB35.698063 million.”

is amended as follows:

“The registered capital of the Company is RMB37.036663 million.”

Article 18, which originally read as:

“The total number of the Company’s shares is 356,980,630 shares, all of which are ordinary shares.”

is amended as follows:

“The total number of the Company’s shares is 370,366,630 shares, all of which are ordinary shares.”

The industrial and commercial registration, filing and other matters in respect of the above amendments to the Articles of Association with the relevant government or regulatory authorities in the PRC will be completed. The full text of the amended Articles of Association is available on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.genfleet.com).

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, October 21, 2025

As at the date of this announcement, the Board comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.